GenomOncology
Latest round
- Series B
Last raised
- Feb 2014
Total raised
- Undisclosed
Investors
- 1
About GenomOncology
GenomOncology focuses on providing precision oncology solutions that enhance cancer care through advanced data interpretation. The company is headquartered in Cleveland, US. The CEO, Bradley Wertz, has led the company since its establishment.GenomOncology specializes in precision oncology solutions designed to improve cancer care through data-driven insights. At the heart of their offerings is the Precision Oncology Platform (POP), which integrates proprietary algorithms and machine learning techniques to transform complex genomic and clinical data into actionable insights. This platform facilitates the seamless processing of genetic test results, providing clinicians with validated, interpretive insights for both somatic and hereditary tests. Additionally, GenomOncology offers data enablement solutions such as igniteIQ, which extracts clinically relevant data from unstructured documents, and GO Connect, which enables genomic data interoperability across various client applications.GenomOncology generates revenue through a combination of subscription-based services and partnerships with healthcare institutions and labs. Their flagship offerings, including the Precision Oncology Platform and the GO Pathology Workbench, are typically sold under multi-year contracts that allow clients to access their suite of software solutions. Transactions are structured as B2B agreements, where organizations pay for licenses and ongoing support, facilitating continuous updates and enhancements to the software. The pricing plans are tiered based on the scale of usage and the specific needs of the client, fostering a scalable approach to adoption and integration within diverse healthcare environments.GenomOncology aims to enhance its product offerings by developing new features within the Precision Oncology Platform and expanding its capabilities in genomic data analysis. The company is also looking to enter new markets, specifically targeting Europe and additional regions in North America by 2015.
Who invested in GenomOncology
1 investor across 1 round
See all investors in GenomOncology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Feb 5, 2014
Amount
Undisclosed
Investors
Questions about GenomOncology
Who invested in GenomOncology?
GenomOncology has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GenomOncology raised?
GenomOncology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did GenomOncology last raise money?
GenomOncology's most recent round on record is a Series B, in Feb 2014.
What does GenomOncology do?
GenomOncology focuses on providing precision oncology solutions that enhance cancer care through advanced data interpretation.
Where is GenomOncology headquartered?
GenomOncology is headquartered in Cleveland, US.
Which VCs invest in companies like GenomOncology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at GenomOncology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like GenomOncology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.